5-amino-1mq and cd38 inhibitor synergy nad+ Selective membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice Discovery of a First-in-Class CD38
Discovery of a First in Class CD38 Inhibitor for the Treatment of Mitochondrial Myopathy Journal of Medicinal Chemistry Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS driven AML: Cell Metabolism Nicotinamide N methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions ScienceDirect NAD+ metabolism and its roles in cellular processes during ageing PMC
Pay in 4 interest-free payments of $6.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15


